bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial ...
The presentation reviewed the robust preclinical findings informing vector and dose selection and demonstrated the positive effects of ... our ability to receive milestone and other payments from our ...